ZURA BIO LTD (ZURA)

KYG9TY5A1016 - Common Stock

2.22  -0.29 (-11.55%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ZURA. ZURA was compared to 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ZURA as it has an excellent financial health rating, but there are worries on the profitability. ZURA is valued expensive and it does not seem to be growing.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

ZURA had negative earnings in the past year.
ZURA had a negative operating cash flow in the past year.

1.2 Ratios

ZURA has a Return On Assets of -22.54%. This is in the better half of the industry: ZURA outperforms 74.34% of its industry peers.
ZURA has a better Return On Equity (-27.85%) than 80.53% of its industry peers.
Industry RankSector Rank
ROA -22.54%
ROE -27.85%
ROIC N/A
ROA(3y)-20.43%
ROA(5y)N/A
ROE(3y)-36.26%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ZURA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, ZURA has more shares outstanding
The debt/assets ratio for ZURA is higher compared to a year ago.

2.2 Solvency

An Altman-Z score of 1.88 indicates that ZURA is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 1.88, ZURA is doing good in the industry, outperforming 70.27% of the companies in the same industry.
ZURA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.88
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

ZURA has a Current Ratio of 10.36. This indicates that ZURA is financially healthy and has no problem in meeting its short term obligations.
ZURA has a better Current ratio (10.36) than 82.48% of its industry peers.
A Quick Ratio of 10.36 indicates that ZURA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 10.36, ZURA belongs to the top of the industry, outperforming 82.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.36
Quick Ratio 10.36

More info and screens

1

3. Growth

3.1 Past

ZURA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 86.21%, which is quite impressive.
EPS 1Y (TTM)86.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ZURA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.99% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y74.94%
EPS Next 2Y31.06%
EPS Next 3Y17.99%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ZURA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ZURA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ZURA's earnings are expected to grow with 17.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.06%
EPS Next 3Y17.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZURA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZURA BIO LTD

NASDAQ:ZURA (12/18/2024, 4:00:00 PM)

2.22

-0.29 (-11.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap144.94M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.54%
ROE -27.85%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 10.36
Quick Ratio 10.36
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)86.21%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y74.94%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y